Sept 16 (Reuters) - Insurer Unum Group (UNM.N) said on Thursday it will launch a new digital product to help companies verify vaccination status of employees, days after the Biden administration mandated large employers should have their workers inoculated against COVID-19.
Sotio, a clinical stage immuno-oncology company owned by PPF Group, has acquired the rights to Unum Therapeutics’ BOXR cell therapy platform and BOXR lead programs to develop novel T cell therapies for the treatment of solid tumors. The proprietary Bolt-on Chimeric Receptor technology incorporates novel transgenes to enhance T cell function in the solid tumor microenvironment.
It’s no secret that Unum Therapeutics has had a tough run—in March, the company cut more than half its staff and wound down its clinical work in a bid to shore up a preclinical CAR-T prospect. Now, that program, along with the technology behind it, has found a new home: Sotio, a Prague-based biotech developing multiple types of cancer treatments.
SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced that it has acquired the rights to Unum Therapeutics’ (Nasdaq: UMRX) BOXR cell therapy platform and BOXR lead programs to develop novel T cell therapies for the treatment of solid tumors. The proprietary Bolt-on Chimeric Receptor technology incorporates novel transgenes to enhance T cell function in the solid tumor microenvironment.
Investors, it seems, are willing to give Unum Therapeutics one last shot — or at least one last shot to a company of that name.
After getting hit with a trio of FDA holds in its brief public history and triggering its second pivot to a new lead drug program while laying off 60% of the staff, the troubled penny stock biotech Unum Therapeutics has hatched new plans to secure financial backing while lining up a go-forward strategy for the company.
Chinese cancer drugs developer InnoCare raises US$289 million